ABSTRACT
The study offers the results from the application of recombinant factor VIIa (NovoSeven) in 19 patients with obstetric or gynaecological problems showing severe haemorrhage of non-surgical origin, which could not be controlled by standard therapy (surgery and resuscitation). Haematological and haemostaseological values as well as final outcome are being monitored. The role of the drug and its special indications in complex urgent treatment of life-threatening bleeding are being discussed. Conclusions. The use of NovoSeven (recombinant factor Vlla) on time and when indicated guarantees rapid and effective haemostasis. Thus laparotomy or relaparotomy can be avoided. If no effect is observed after the application of NovoSeven indicates bleeding from a major blood vessel, demanding laparotomy and surgery. The use of the drug leads to reducing the incidence of blood derivatives transfusions and (being a recombinant product)--no risk of transmissive infections.
Subject(s)
Factor VIIa/therapeutic use , Gynecology , Hemorrhage/drug therapy , Hemostatics/therapeutic use , Obstetrics , Factor VIIa/chemistry , Factor VIIa/genetics , Female , Humans , Models, Biological , Molecular Structure , Pregnancy , Recombinant Proteins/chemistry , Recombinant Proteins/therapeutic use , Treatment OutcomeABSTRACT
We report our clinical opinion for recombinant activated factor VII (NovoSeven, Novo Nordisk, Copenhagen, Denmark) administration in gynecology patients with massive haemorrhage. 3 women with gynecology deseases and severe bleeding in recieved NovoSeven in bolus IV. The blood loss and laboratory changes in hematology and haemostasis parameters are monitored. The bleeding was ceased in all cases. Decrease in values of Hb, Er and PTT was noted. The use of recombinant factor VIIA in gynecology patients with severe bleeding is effective and safe enough and could be an alternative to the extreme surgical procedures.
Subject(s)
Factor VII/therapeutic use , Genital Diseases, Female/drug therapy , Hemorrhage/drug therapy , Recombinant Proteins/therapeutic use , Adult , Child , Factor VII/administration & dosage , Factor VIIa , Female , Genital Diseases, Female/blood , Hemorrhage/blood , Hemostasis/drug effects , Humans , Injections, Intravenous , Middle Aged , Recombinant Proteins/administration & dosage , Treatment OutcomeABSTRACT
We report our clinical opinion for recombinant activated factor VII (NovoSeven, Novo Nordisk, Copenhagen, Denmark) administration in puerperae with massive haemorrhage caused by uterine hypotonia. Four women with severe bleeding in post-placental period received NovoSeven in bolus IV. The blood loss and laboratory changes in hematology and haemostasis parameters are monitored. The right time of application and the mean effective dose of the medication are discussed. The bleeding was ceased in all cases. Decrease in values of Hb, Er and PTT was noted. The mean administered dose of 72 micrograms/kg BW was effective. The laboratory values showed tendency for improvement on the 24 hour after administration and normal levels on discharge. The use of recombinant factor VIIA in puerperae with severe bleeding in the postplacental period is effective and safe enough and could be an alternative to the extreme surgical procedures.
